Press Releases

Date Title
August 31, 2016
Oncobiologics to Present at BioCentury’s NewsMakers in the Biotech Industry Conference
CRANBURY, N.J. , Aug. 31, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and
July 6, 2016
Oncobiologics, Inc. to Present at the 2016 Cantor Fitzgerald 2nd Annual Healthcare Conference
CRANBURY, N.J. , July 06, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody (mAb) biosimilar therapeutics, today announced that its Chairman, CEO and
June 16, 2016
Oncobiologics Announces First CTA Approvals for Global Phase 3 Clinical Program for ONS-3010 (Humira® biosimilar)
Clinical Program Designed to Enable Interchangeability with Humira in U.S. CRANBURY, N.J. , June 16, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONS), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal
June 10, 2016
Oncobiologics Announces Separation of Units; Trading of Common Stock and Warrants
CRANBURY, N.J. , June 10, 2016 (GLOBE NEWSWIRE) -- Oncobiologics, Inc. (NASDAQ:ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex monoclonal antibody biosimilar therapeutics, today announced that the 5,833,334 units
May 18, 2016
Oncobiologics Announces Closing of Initial Public Offering of Units
Cranbury, NJ – May 18, 2016 — Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced that it successfully closed its previously announced initial public
May 12, 2016
Oncobiologics Announces Pricing of Its Initial Public Offering of Units
CRANBURY, N.J. , May 12, 2016 /PRNewswire/ --  Oncobiologics, Inc. (NASDAQ: ONSIU), a clinical-stage biopharmaceutical company focused on identifying, developing, manufacturing and commercializing complex biosimilar therapeutics, today announced the pricing of its initial public offering of
December 14, 2015
Oncobiologics Expands Its Board Of Directors With The Appointment Of Three New Independent Members
Oncobiologics Expands its Board of Directors with the Appointment of Three New Independent Members Cranbury, NJ – December 14, 2015 — Oncobiologics, Inc. (Oncobiologics) announces the expansion of its Board of Directors with the appointment of Albert D. Dyrness, Kurt J.
October 5, 2015
ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial
Oncobiologics Announces ONS-1045 (Avastin®/bevacizumab biosimilar) Meets Primary and Secondary Endpoints in Phase 1 Clinical Trial Cranbury, NJ – Oct. 5, 2015 — Oncobiologics, Inc. (“Oncobiologics”) announced that its bevacizumab (Avastin®) biosimilar candidate, ONS-1045, met the primary and
September 29, 2015
Oncobiologics Secures Financing from Sabby Management, LLC
Oncobiologics Secures Financing from Sabby Management, LLC to Advance BioSymphony TM Platform and Monoclonal Antibody Biosimilars Pipeline Cranbury, NJ – Sept. 29, 2015 — Oncobiologics, Inc. (“Oncobiologics”) announced that it closed an additional round of financing with Sabby Management, LLC.
September 16, 2015
Oncobiologics Appoints Lawrence A. Kenyon as Chief Financial Officer
Oncobiologics, Inc. announced the appointment of Lawrence A. Kenyon as its Chief Financial Officer (CFO), effective September 15, 2015. Mr. Kenyon is an accomplished executive with extensive experience managing the financial and business operations of emerging and established private and public
Displaying 41 - 50 of 61